Skip to main content
Equibles

GOLDMAN SACHS GROUP INC

Position in NBIX — Neurocrine Biosciences Inc

CIK 886982 NEW YORK, NY
Back to NBIX Full portfolio

Position in NBIX

as of Mar 31, 2026 · filed May 15, 2026
Position Value
$46,000,839
-$5,701,158 QoQ
Shares Held
349,179
-4.2% QoQ
Ownership
0.347%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2020
25 quarters on record
Voting authority Sole 89.63769298840995.ToString("F0")% Shared 0.8499938426995896.ToString("F0")% None 9.512313168890454.ToString("F0")%

Common Shares in NBIX Over Time

Shares Held

Position Value (USD)

Derivatives in NBIX

reported options exposure · as of Mar 31, 2026
CallValue
$0
CallShares
0
PutValue
$1,804,838
PutShares
13,700

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Drug Manufacturers - Specialty & Generic

Healthcare · as of Mar 31, 2026

GOLDMAN SACHS GROUP INC holds $1,741,757,397 across 53 Drug Manufacturers - Specialty & Generic names. NBIX ranks #10 (2.6% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 ZTS
Zoetis Inc.
 3,730,785 $441,016,092
2 VTRS
Viatris Inc
 13,717,622 $185,325,071
3 TEVA
Teva Pharmaceutical Industries Ltd
 4,826,245 $145,366,498
4 TAK
Takeda Pharmaceutical Co Ltd
 5,618,728 $104,058,841
5 INDV
Indivior Pharmaceuticals, Inc.
 2,409,165 $73,431,349
6 UTHR
UNITED THERAPEUTICS Corp
 114,419 $67,848,177
7 ALKS
Alkermes plc.
 1,882,178 $66,553,812
8 HLN
Haleon plc
 6,127,452 $61,335,793

All Filings in NBIX

Export CSV
39 filing rows on record
Report Date Value (USD) Shares
2026-03-31 $46,000,839 349,179
2026-03-31 $1,804,838 13,700
2025-12-31 $354,575 2,500
2025-12-31 $51,701,997 364,535
2025-09-30 $350,950 2,500
2025-09-30 $85,577,471 609,613
2025-06-30 $402,208 3,200
2025-06-30 $1,420,297 11,300
2025-06-30 $86,206,370 685,865
2025-03-31 $81,560,531 737,437
2024-12-31 $134,288,563 983,799
2024-09-30 $117,196,481 1,017,154
2024-06-30 $155,923,526 1,132,589
2024-03-31 $106,988,266 775,727
2023-12-31 $91,129,431 691,632
2023-09-30 $88,532,437 786,955
2023-06-30 $77,763,269 824,637
2023-03-31 $98,163,154 969,800
2022-12-31 $158,821,995 1,329,722
2022-09-30 $127,642,115 1,201,790
2022-06-30 $122,320,145 1,254,823
2022-03-31 $140,292,374 1,496,452
2021-12-31 $2,555,100 30,000
2021-12-31 $2,555,100 30,000
2021-12-31 $129,842,942 1,524,515
2021-09-30 $138,445,892 1,443,498
2021-06-30 $13,624,800 140,000
2021-06-30 $138,514,387 1,423,288
2021-03-31 $13,615,000 140,000
2021-03-31 $136,876,846 1,407,474
2020-12-31 $14,875,920 155,200
2020-12-31 $116,722,774 1,217,765
2020-09-30 $85,502,682 889,171
2020-09-30 $6,279,248 65,300
2020-06-30 $6,112,200 50,100
2020-06-30 $115,249,618 944,669
2020-03-31 $2,830,185 32,700
2020-03-31 $5,201,655 60,100
2020-03-31 $78,075,196 902,082

Report a Problem

Category
Description
Email (optional, for follow-up)